The cohort also included cancers with a mix of molecular subgroups [16% epidermal growth factor receptor (EGFR)-positive aNSCLC, 48% RAS-positive mCRC] and sites of disease (e.g. bone, liver, brain). The gene discussed is EGFR; the disease is cancer.